AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Kuros Biosciences Ltd.

Earnings Release Apr 28, 2011

916_rns_2011-04-28_442fa71f-68e9-484b-9a27-834e400936b7.html

Earnings Release

Open in Viewer

Opens in native device viewer

News Details

Corporate | 28 April 2011 07:00

Cytos Biotechnology First Quarter Report 2011

Cytos Biotechnology AG / Key word(s): Quarter Results

28.04.2011 / 07:00

Cytos Biotechnology Ltd First Quarter Report 2011 as of March 31, 2011

Summary of important events in Q1 2011

  • United States Army and Cytos Biotechnology collaborate on malaria vaccines research
  • Cytos Biotechnology receives EU funding to work on novel vaccine approaches for emerging viral diseases
  • Cytos Biotechnology presented latest data on the mechanism of action of QbG10 for the treatment of allergic asthma at the 3rd International Conference on Drug Discovery and Therapy in Dubai
  • Upcoming event:
    • Presentation at the Active Immunotherapeutics Forum, May 11-13, 2011 in Barcelona, Spain
  • Financial summary
in CHF million Q1 2011 Q1 2010
Revenue 0.6 0.3
Net operating costs (5.5) (6.9)
Net loss (5.3) (3.8)
03/31/11 12/31/10
Cash, cash equivalents, 42.0 48.7
financial assets
and trade and other receivables
Convertible bonds 41.1 41.1
(outstanding nominal value)
Full-time equivalents (number) 75 81

The complete First Quarter Report 2011 can be downloaded on Cytos Biotechnology's website under the following link:

http://www.cytos.com/userfiles/file/Cytos_Q1_2011_E.pdf

For more information please contact:

Harry Welten, MBA

Chief Financial Officer

Cytos Biotechnology Ltd

Wagistrasse 25, Postfach

CH-8952 Schlieren (Zurich)

Tel. +41 44 733 46 46

e-mail: [email protected]

www.cytos.com

End of Corporate News


28.04.2011 News transmitted by EquityStory AG.

The issuer is responsible for the contents of the release.

EquityStory publishes regulatory releases, media releases on the capital market and press releases.

The EquityStory Group distributes authentic and real-time financial news for over 1’300 listed companies.

The Swiss news archive can be found at http://www.equitystory.ch/nachrichten


Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Schweiz
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: [email protected]
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Swiss Security Number:
Listed: Regulierter Markt in SIX; Freiverkehr in Berlin, München, Stuttgart; Open Market in Frankfurt
End of News EquityStory AG News-Service
- - -
121664  28.04.2011

Talk to a Data Expert

Have a question? We'll get back to you promptly.